The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Open accessAbstract
Purpose: The proteasome inhibitor bortezomib may enhance activity of chemoimmunotherapy in lymphoma. We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Patients and Methods: Seventy-six subjects with untreated DLBCL (n = 40) and MCL (n = 36) received standard CHOP every 21 days (CHOP-21) with R plus bortezomib at 0.7 mg/m 2(n = 4), 1.0 mg/m 2(n = 9), or 1.3 mg/m 2(n = 63) on days 1 and 4 for six cycles. Results: Median age was 63 years (range, 20 to 87), and International Prognostic Index (IPI) scores were generally unfavorable (39% with IPI of 2, and 49% with IPI of 3 to 5), as were Mantle Cell Lymphoma International Prognostic Index scores in patients with MCL (28% intermediate risk and 39% high risk). Toxicity was manageable, including neuropathy in 49 subjects (8% grade 2 and 4% grade 3) and grade 3/4 anemia (13%), neutropenia (41%), and thrombocytopenia (25%). For DLBCL, the evaluable overall response rate (ORR) was 100% with 86% complete response (CR)/CR unconfirmed (CRu; n = 35). Intent-to-treat (ITT, n = 40) ORR was 88% with 75% CR/CRu, 2-year progression-free survival (PFS) of 64% (95% CI, 47% to 77%) and 2-year overall survival (OS) of 70% (95% CI, 53% to 82%). For MCL, the evaluable ORR was 91% with 72% CR/CRu (n = 32). The ITT (n = 36) ORR was 81% with 64% CR/CRu, 2-year PFS 44% (95% CI, 27% to 60%) and 2-year OS 86% (95% CI, 70% to 94%). IPI and MIPI correlated with survival in DLBCL and MCL, respectively. Unlike in DLBCL treated with R-CHOP alone, nongerminal center B cell (non-GCB) and GCB subtypes had similar outcomes. Conclusion: Bortezomib with R-CHOP-21 can be safely administered and may enhance outcomes, particularly in non-GCB DLBCL, justifying randomized studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationHans, C. P. (2004) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 3,703
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationShipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.-L., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70664-7 · Cited by 2,076
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationContinual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,486
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,355
Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70002-0 · Cited by 1,130
Davis, R. E., Brown, K. D., Siebenlist, U., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,051
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., Carty, S., Lam, L. T., Shaffer, A. L., Xiao, W., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804295105 · Cited by 995
Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J. J., Sutherland, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.137 · Cited by 987
Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Muller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 914
Self-citationThe development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Self-citationO'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.050 · Cited by 577
Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1825 · Cited by 557
Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
Cheung, Y. K., & Chappell, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.01177.x · Cited by 545
Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.108 · Cited by 526
Dunleavy, K., Pittaluga, S., Czuczman, M. S., Dave, S. S., Wright, G., Grant, N., Shovlin, M., Jaffe, E. S., Janik, J. E., Staudt, L. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199679 · Cited by 497
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.8435 · Cited by 399
Howard, O. M., Gribben, J. G., Neuberg, D. S., Grossbard, M. L., Poor, C., Janicek, M. J., & Shipp, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1288 · Cited by 372
Wilson, W. H., Dunleavy, K. M., Pittaluga, S., Hegde, U. P., Grant, N., Steinberg, S. M., Raffeld, M. A., Gutierrez, M. E., Chabner, B. A., Staudt, L. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1391 · Cited by 326
Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., & Ford, R. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.88 · Cited by 320
Lam, L. T., Davis, R. E., Pierce, J., Hepperle, M. E., Xu, Y., Foley, M. H., Nong, Y., Wen, D., Adams, J., Dang, L., et al. (2005) · PubMed · Cited by 312
Determann, O., Hoster, E., Ott, G., Wolfram Bernd, H., Loddenkemper, C., Leo Hansmann, M., Barth, T. E. F., Unterhalt, M., Hiddemann, W., Dreyling, M., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117010 · Cited by 238
Lam, L. T., Davis, R. E., Pierce, J., Hepperle, M., Xu, Y., Hottelet, M., Nong, Y., Wen, D., Adams, J., Dang, L., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.28.11.1 · Cited by 229
State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma
Coiffier, B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.015 · Cited by 178
Belch, A. R., Kouroukis, C. T., Crump, M., Sehn, L. H., Gascoyne, R. D., Klasa, R. J., Powers, J., Wright, J. R., & Eisenhauer, E. A. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl316 · Cited by 162
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Thall, P. F., Simon, R. M., & Estey, E. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.296 · Cited by 131
de Vos, S., Goy, A. H., Dakhil, S. R., Saleh, M. N., McLaughlin, P. J., Belt, R. J., Flowers, C. R., Knapp, M. H., Hart, L. L., Patel‐Donnelly, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7980 · Cited by 98
Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non–Hodgkin's Lymphoma
Ruan, J., Hyjek, E. M., Kermani, P., Christos, P. J., Hooper, A. T., Coleman, M., Hempstead, B. L., Leonard, J. P., Chadburn, A., & Rafii, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1204 · Cited by 88
Self-citationWang, M., Han, X., Zhang, L., Yang, J., Qian, J. F., Shi, Y., Kwak, L. W., Romaguera, J. E., & Yi, Q. (2007) · Leukemia · doi:10.1038/sj.leu.2404959 · Cited by 87
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
Gerecitano, J. F., Portlock, C. S., Moskowitz, C. H., Hamlin, P. A., Straus, D. J., Zelenetz, A. D., Zhang, Z., Dumitrescu, O., Sarasohn, D. M. M., Lin, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07775.x · Cited by 48
Longley, D. B., Latif, T., Boyer, J. L., ALLEN, W., Maxwell, P., & Johnston, P. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70019-0 · Cited by 44
Longley, D. B., Latif, T., Boyer, J., Allen, W. L., Maxwell, P. J., & Johnston, P. G. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00119-2 · Cited by 37
Mantle Cell Lymphoma: Current Concept in Biology and Treatment
Ruan, J., & Leonard, J. P. (2008) · Springer eBooks · doi:10.1007/978-0-387-29346-2_5 · Cited by 7
Self-citation
Cited by
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Liu, Y., & Barta, S. K. (2019) · American Journal of Hematology · doi:10.1002/ajh.25460 · Cited by 488
Martelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Pathogenesis of Human B Cell Lymphomas
Shaffer, A. L., Young, R. M., & Staudt, L. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075027 · Cited by 437
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 411
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412096 · Cited by 386
Metadata
- Authors
- Ruan, J., Martin, P., Furman, R. R., Lee, S. M., Cheung, K., Vose, J. M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., Chadburn, A., Cesarman, E., Coleman, M., & Leonard, J. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-02-20
- Volume
- 29
- Issue
- 6
- Pages
- 690-697
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2111530307
- Cited by
- 319
- References
- 44
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.